Investor Materials

View our latest investor materials below:

Letter to Shareholders

October 29, 2021

Letter to Shareholders Thumbnail image

Latest Financial Results

FY 2020

Fiscal Year Ended Dec 31, 2020

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020



Company Overview

FSD Pharma is a life sciences holding company dedicated to building a portfolio of diversified therapeutic assets and innovative healthcare and biotech services. The Company is currently advancing a pipeline of innovative therapeutics that target Total Brain Health with multiple lead clinical candidates addressing a variety of neurodegenerative and neuropsychiatric diseases.

Through its wholly-owned subsidiary, Lucid Psycheceuticals, FSD has exclusive worldwide rights to novel compounds shown to reverse the underlying cause of progressive Multiple Sclerosis. Additionally, FSD is developing a unique psychedelic-based therapeutic aimed to address a multibillion-dollar mental health market. The Company plans to quickly advance its lead drug candidates through clinical trials to one day change the minds and bodies of millions of patients for the better.

Investor Contact Information

Company

FSD Pharma Inc.
199 Bay St.
Suite 4000
Toronto, ON M5L 1A9
Canada

Investor Relations

FSDPharma@KCSA.com

Transfer Agent

Computershare Trust Corporation
https://www.computershare.com/us